Aldeyra Therapeutics to Participate at the 2017 Ra

LEXINGTON, MA--(Marketwired - Feb 6, 2017) - Aldeyra Therapeutics, Inc. ( NASDAQ : ALDX ) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at the 2017 Rare Disease, Biopharma One-on-One Day on Tuesday, February 7, 2017.

Event: 2017 Rare Disease, Biopharma One-on-One Day Date: Tuesday, February 7, 2017 Location: Intercontinental Barclay, 111 E 48 ^th St, New York, NY

About Aldeyra Therapeutics Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.